• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2012 Fiscal Year Final Research Report

Development of innovative anti-tumor agents that target signal transducers and activator of transcription

Research Project

  • PDF
Project/Area Number 23659487
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Hematology
Research InstitutionNagoya University

Principal Investigator

NAOE Tomoki  名古屋大学, 医学系研究科, 教授 (50217634)

Project Period (FY) 2011 – 2012
Keywordsシグナル伝達 / STAT3 / STAT5 / FLT3
Research Abstract

We demonstrated that a novel STAT inhibitor, OPB-31121, strongly inhibited STAT3 and STAT5 phosphorylation without upstream kinase inhibition, and induced significant growth inhibition in various hematopoietic malignant cells. Investigation among various cell lines indicated that OPB-31121 is particularly effective on leukemia cells harboring BCR-ABL, FLT3/ITD and JAK2 V617F, oncogenic kinases depended their oncogenicities on STAT3/5. Using immunodeficient mice transplantation system, we also showed the significant anti-tumor effect of OPB-31121 on primary human leukemia cells harboring those aberrant kinases and the safety on normal human cord blood.

  • Research Products

    (14 results)

All 2012 2011 2010

All Journal Article (10 results) (of which Peer Reviewed: 10 results) Presentation (4 results)

  • [Journal Article] B Cell Receptor-ERK1/2 Signal Cancels PAX5-Dependent Repression of BLIMP1 through PAX5 Phosphorylation: A Mechanism of Antigen-Triggering Plasma Cell Differentiation2012

    • Author(s)
      Yasuda T, Hayakawa F, Kurahashi S, Sugimoto K, Minami Y, Tomita A, Naoe T.
    • Journal Title

      J Immunol.

      Volume: 188 Pages: 6127-6134

    • Peer Reviewed
  • [Journal Article] CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-7372012

    • Author(s)
      Shimada K, Tomita A, Minami Y, Abe A, Hind CK, Kiyoi H, Cragg MS, Naoe T
    • Journal Title

      Exp Hematol

      Volume: 40 Pages: 724-737

    • Peer Reviewed
  • [Journal Article] Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib2012

    • Author(s)
      Mizuno H, Nakayama T, Miyata Y, Saito S, Nishiwaki S, Nakao N, Takeshita K, Naoe T
    • Journal Title

      Leukemia

      Volume: 26 Pages: 2269-2276

    • Peer Reviewed
  • [Journal Article] Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan2012

    • Author(s)
      Tokunaga T, Shi mada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, Tanimoto M, Iwasaki T, Isoda A, Sakai A, Kobayashi H, Kitamura K, Matsue K, Taniwaki M, Tamashima S, Saburi Y, Masunari T, Naoe T, Nakamura S, Kinoshita T
    • Journal Title

      Blood

      Volume: 119 Pages: 2837-2843

    • Peer Reviewed
  • [Journal Article] Missense mutations in PML-RARA critical for the lack of responsiveness to arsenic trioxide treatment2011

    • Author(s)
      Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T
    • Journal Title

      Blood

      Volume: 118 Pages: 1600-1609

    • Peer Reviewed
  • [Journal Article] The mTOR inhibitor, everolimus (RAD001), overcomes resistanceto imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells2011

    • Author(s)
      Kuwatsuka Y, Minami M, Minami Y, Sugimoto K, Hayakawa F, Miyata Y, Abe A, Goff DJ, Kiyoi H, Naoe T
    • Journal Title

      Blood Cancer J

      Volume: 1(5) Pages: e17

    • Peer Reviewed
  • [Journal Article] A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis2011

    • Author(s)
      Sakai K, Ishikawa Y, Mori Y, Kobayashi M, Iriyama C, Ozawa Y, Suzuki T, Minami Y,Ishikawa K, Kaneda N, Naoe T, Kiyoi H
    • Journal Title

      Int J Hematol

      Volume: 93 Pages: 237-242

    • Peer Reviewed
  • [Journal Article] PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML2011

    • Author(s)
      Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S, Abe A, Naoe T
    • Journal Title

      Oncogene

      Volume: 30 Pages: 1822-1830

    • Peer Reviewed
  • [Journal Article] Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment2010

    • Author(s)
      Minami Y, Kajiguchi T, Abe A, Ohno T, Kiyoi H, Naoe T
    • Journal Title

      Int J Hematol

      Volume: 92 Pages: 664-666

    • Peer Reviewed
  • [Journal Article] Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia2010

    • Author(s)
      Tsujimura A, Kiyoi H, Shiotsu Y, Ishikawa Y, Mori Y, Ishida H, Toki T, Ito E, Naoe T
    • Journal Title

      Int J Hematol

      Volume: 92 Pages: 624-633

    • Peer Reviewed
  • [Presentation] Wnt Signaling Is Associated with Anti-Apoptosis in the Interaction Between Acute Myeloid Leukemia Cells and Stromal Cells2012

    • Author(s)
      Yosuke Minami, Yosuke Niwa, Akihiro Abe, Fumihiko Hayakawa, and Tomoki Naoe
    • Organizer
      The American Society of Hematology 54th Annual Meeting
    • Place of Presentation
      Atlanta (USA).
    • Year and Date
      2012-12-08
  • [Presentation] Drug Development Targeting Microenvironment for Malignant Lymphoma ASH Annual Meeting Abstracts 2012 120:16612012

    • Author(s)
      Keiki Sugimoto, Fumihiko Hayakawa, Takahiko Yasuda, and Tomoki Naoe
    • Organizer
      The American Society of Hematology 54th Annual Meeting
    • Place of Presentation
      Atlanta (USA)
    • Year and Date
      2012-12-08
  • [Presentation] A Novel STAT3 Inhibitor OPB-31121 Induces Tumor-Specific Growth Inhibition in a Wide Range of Hematopoietic Malignancies without Growth Suppression of Normal Hematopoietic Cells2011

    • Author(s)
      Hayakawa F, Sugimoto K, Kurahashi S, Sumida T, Naoe T.
    • Organizer
      The American Society of Hematology 53th Annual Meeting
    • Place of Presentation
      San Diego, USA
    • Year and Date
      2011-12-10
  • [Presentation] Retention of Slow-Cycling CD34+ cells During Imatinib Treatment and Rapid Decline After 2ndABL-TKI Treatment in Ph+ Leukemia Cells2011

    • Author(s)
      Minami Y, Abe A, Minami M, Kuwatsuka Y, Fukushima N, Kitamura K, Hiraga J, Yamamoto K, Jamieson C, Naoe T
    • Organizer
      The American Society of Hematology 53th Annual Meeting
    • Place of Presentation
      San Diego, USA
    • Year and Date
      2011-12-10

URL: 

Published: 2014-09-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi